Genmab — Oktober 2024
-
or this one “conditions for M&A are favorable,” according to a research note from Morgan Stanley. https://www.fiercepharma.com/pharma/firepower-aplenty-and-patent-cliffs-ahead-time-right-ma-activity-report or M&A
-
but rumours have been there for a long time
https://invivo.citeline.com/SC004123/Genmab-a-potential-target-for-GSK -
Journalisten - søg på I dreamed a dream fra Les Miserables. Det er ren ønsketænkning
-
Godmorgen
-
Der kan også være fonde m.m., der har stop-loss på deres Genmab-aktier. Uanset hvor gode nyhederne måtte være, er de måske nødt til at overholde deres stop-loss-regler. Jeg formoder, at de har regler, de skal følge, og de kan ikke bare sidde og se på, at en aktie falder 50% uden at handle. Dette kan muligvis være med til at forstærke nedturen.
-
Opdivo wins FDA label expansion in perioperative NSCLC https://firstwordpharma.com/story/5901073
-
I would guess they can but not sure. In the Duobody agreement the partner pays a smaller amount in the beginning of a program and gets exclusivity for a shorter period of time. My understanding hereafter that others could persue same target combination. Zymeworks for instance had no exclusivity on their BsAb platform
-
similar thoughts/doubts
Sukkeralf https://x.com/JacobPlieth/status/1842115371467219052 -
Tak for svar og lidt som ventet, - at der tilsyneladende aldrig har været seriøse rygter om Genmab som opkøbsmål, - bortset altså tilbage i 2009.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind